Olanzapine and Fluoxetine combination (OFC) + Fluoxetine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment Resistant Depression
Conditions
Treatment Resistant Depression
Trial Timeline
Aug 1, 2009 → Mar 1, 2012
NCT ID
NCT00958568About Olanzapine and Fluoxetine combination (OFC) + Fluoxetine
Olanzapine and Fluoxetine combination (OFC) + Fluoxetine is a phase 3 stage product being developed by Eli Lilly for Treatment Resistant Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00958568. Target conditions include Treatment Resistant Depression.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00958568 | Phase 3 | Completed |
Competing Products
20 competing products in Treatment Resistant Depression